Hohimer Wealth Management LLC Buys Shares of 76,600 NovoCure Limited $NVCR

Hohimer Wealth Management LLC purchased a new position in NovoCure Limited (NASDAQ:NVCR) during the 3rd quarter, Holdings Channel reports. The fund purchased 76,600 shares of the medical equipment provider’s stock, valued at approximately $990,000.

A number of other hedge funds have also recently modified their holdings of the business. Soleus Capital Management L.P. increased its stake in shares of NovoCure by 25.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock worth $122,897,000 after purchasing an additional 1,382,888 shares in the last quarter. Balyasny Asset Management L.P. lifted its position in NovoCure by 38.8% during the second quarter. Balyasny Asset Management L.P. now owns 2,270,076 shares of the medical equipment provider’s stock valued at $40,407,000 after purchasing an additional 634,925 shares in the last quarter. Quantinno Capital Management LP grew its holdings in NovoCure by 38.5% during the second quarter. Quantinno Capital Management LP now owns 1,368,663 shares of the medical equipment provider’s stock valued at $24,362,000 after purchasing an additional 380,411 shares during the period. American Century Companies Inc. grew its holdings in NovoCure by 1,354.7% during the second quarter. American Century Companies Inc. now owns 1,029,874 shares of the medical equipment provider’s stock valued at $18,332,000 after purchasing an additional 959,079 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in NovoCure by 5.5% in the first quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider’s stock worth $17,707,000 after buying an additional 52,180 shares in the last quarter. Institutional investors own 84.61% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NVCR. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Evercore set a $20.00 target price on shares of NovoCure in a research note on Monday, January 5th. HC Wainwright lifted their price target on shares of NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a report on Thursday. Finally, Wedbush reiterated a “neutral” rating and issued a $18.00 price target on shares of NovoCure in a research report on Thursday, January 15th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $26.93.

Key Headlines Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (loss of $0.22 vs. est. -$0.41) and revenue was essentially in line, with revenue up ~8% year‑over‑year — evidence of top‑line momentum as the company scales. Article Title
• Positive Sentiment: Management raised FY‑2026 revenue guidance to $675M–$705M, above consensus (~$670M), which supports revenue growth expectations for the year ahead. Article Title
• Positive Sentiment: HC Wainwright increased its price target (to $49) and maintained a Buy rating — a bullish analyst call that could support investor interest given the large implied upside vs. current levels. Article Title
• Neutral Sentiment: Analyst coverage is mixed but active — a recent Benzinga deep dive summarizes four analyst viewpoints, useful for gauging near‑term sentiment and differential expectations. Article Title
• Neutral Sentiment: The full earnings call transcript and slide deck are available — management discussed strategic growth initiatives (market expansion and commercial execution), which investors should review for details on cadence and investments. Article Title
• Negative Sentiment: Despite revenue growth and beats, NovoCure remains loss‑making with a negative net margin (~27.7%) and negative ROE; analysts still model a negative EPS for the year, keeping valuation and profitability concerns front‑of‑mind. Article Title
• Negative Sentiment: Management flagged operational challenges on the call (execution and other near‑term issues), which could constrain margin improvement and near‑term cash flow conversion. Article Title

NovoCure Stock Down 0.6%

Shares of NVCR opened at $13.67 on Friday. The business’s 50 day moving average is $12.73 and its 200 day moving average is $12.65. The company has a market capitalization of $1.53 billion, a PE ratio of -11.20 and a beta of 0.73. NovoCure Limited has a 12-month low of $9.82 and a 12-month high of $21.55. The company has a current ratio of 1.55, a quick ratio of 1.50 and a debt-to-equity ratio of 0.57.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.19. The business had revenue of $174.35 million during the quarter, compared to the consensus estimate of $174.40 million. NovoCure had a negative return on equity of 38.82% and a negative net margin of 20.79%.The firm’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.61) EPS. Research analysts expect that NovoCure Limited will post -1.3 earnings per share for the current fiscal year.

NovoCure Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.